United States Dopamine Agonists Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

Dopamine Agonists Market reached US$ 1,148.88 Million in 2024 and is expected to reach US$ 1,732.41 Million by 2033, growing at a CAGR of 5.4 % during the forecast period 2025-2033.

Key Development:

United States: Recent Industry Developments

✅ In September 2025, AbbVie submitted a New Drug Application to the U.S. FDA for tavapadon, a selective dopamine D1/D5 receptor agonist for Parkinson's disease. Phase 3 trials demonstrated significant improvements in motor function and reduced motor fluctuations.

✅ In June 2025, researchers introduced ENX-104, a low-dose dopamine D2/D3 autoreceptor antagonist aimed at enhancing dopaminergic neurotransmission. This oral agent is under investigation for its potential in treating conditions like depression and schizophrenia.

✅ In May 2025, Alto Neuroscience acquired ALTO-207, a novel dopamine agonist combination therapy for treatment-resistant depression. This late-stage candidate combines pramipexole and ondansetron to enhance efficacy while minimizing side effects.

Japan: Recent Industry Developments

✅ In September 2025, the Japan Bank for International Cooperation (JBIC) made an equity investment in Metagen Therapeutics, a Japanese startup developing drugs based on gut microbiota research. This investment supports the company's innovative approach to drug development.

✅ In August 2025, Japan's AMED introduced the 'Double Match Up' grant program, offering grants up to JPY 6.7 billion (approximately USD 44.5 million) to biopharma startups with approved pipelines. This initiative aims to accelerate pharmaceutical innovation in Japan.

✅ In August 2025, Japan's Ministry of Health, Labour and Welfare invested an additional USD 1 million to support GARDP's activities, bringing the total investment to USD 10 million since 2020. This funding aims to develop new treatments for drug-resistant infections.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/dopamine-agonists-market?sb

Key Players:

=> Teva Pharmaceuticals USA, Inc., GSK plc, UCB S.A., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Boehringer Ingelheim International GmbH, Wellona Pharma, Glenmark Pharmaceuticals Inc., AdvaCare Pharma, and Serum Institute of India Pvt. Ltd., among others.

Emerging Players:

=> Cerevel Therapeutics, Inhibikase Therapeutics, Inc., Neuraly Inc., and Peptron, among others.

Growth Forecast Projected:

The Global Dopamine Agonists Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Dopamine Agonists Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=dopamine-agonists-market

Key Segments:

➥ By Product Type: Ergot-Based Dopamine Agonists (Bromocriptine, Cabergoline, Others), Non-Ergot-Based Dopamine Agonists (Pramipexole, Ropinirole, Rotigotine, Amantadine, Apomorphine, Fenoldopam, Others)

➥ By Route of Administration: Oral, Parenteral, Transdermal Patches

➥ By Application: Parkinson's Disease, Antipsychotic Agents, Hyperprolactinemia, Type 2 Diabetes, Restless Legs Syndrome (RLS), Neuroleptic Malignant Syndrome, Others

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Dopamine Agonists Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Dopamine Agonists producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Dopamine Agonists revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/dopamine-agonists-market?sb

FAQ

What is the current size of the Dopamine Agonists Market?

A: In 2024, the Dopamine Agonists Market was valued at US$ 1,148.88 Million , reflecting its strong industry presence.

Q2: How large is the Dopamine Agonists Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Dopamine Agonists Market will grow to around US$ 1,732.41 Million , demonstrating significant expansion.

Q3: What is the growth rate of the Dopamine Agonists Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5.4 % during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us
-

Company
Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.